调强放疗下化疗在Ⅱ期鼻咽癌中的研究现状  

Current status of chemotherapy under intensity-modulated radiotherapy in stage Ⅱ nasopharyngeal carcinoma

作　　者：叶祯开[1] YE Zhenkai(Department of Radiotherapy,Minzu Hospital of Guangxi Zhuang Autonomous Region,Nanning 530001,China)

机构地区：[1]广西壮族自治区民族医院放疗科

出　　处：《中国现代医生》2019年第26期165-168,共4页China Modern Doctor

摘　　要：放化疗是Ⅱ期鼻咽癌治疗的标准方案.调强放射治疗技术的优势让多数患者仅采用单纯IMRT放疗,5年总生存率达90%以上,主要通过较高的局部控制率而改善预后.由于Ⅱ期鼻咽癌远处转移率低,联合化疗不能改善其总生存,反而增加急性毒性反应,导致生活质量下降.T2N1亚组疗效较差,原因与远处转移风险较高有关,有必要联合化疗,但有效的化疗方案有待研究.Synchronous radiotherapy and chemotherapy under 2D conventional radiotherapy is the standard treatment for stage Ⅱ nasopharyngeal carcinoma. The advantages of intensity-modulated radiotherapy technology make most patients only use IMRT radiotherapy alone. The 5-year overall survival rate is over 90%, which is mainly to improve the prognosis through higher local control rate. Because of the low distant metastasis rate of stage Ⅱ nasopharyngeal carcinoma, combined chemotherapy can not improve their overall survival, but increase acute toxicity, leading to a decline in quality of life. The T2N1 subgroup is less effective, and the reason is related to the higher risk of distant metastasis. The combination of chemotherapy is necessary, but an effective chemotherapy regimen remains to be studied.

关 键 词：调强放射治疗 鼻咽恶性肿瘤 Ⅱ期 化学治疗 

分 类 号：R739.6[医药卫生—肿瘤]